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Abstract
Background: Most cancer deaths result from tumor cells that have metastasized beyond their tissue of origin, or
have developed drug resistance. Across many cancer types, patients with advanced stage disease would benefit
from a novel therapy preventing or reversing these changes. To this end, we have investigated the unique WR
domain of the transcription factor TWIST1, which has been shown to play a role in driving metastasis and drug
resistance.
Methods: In this study, we identified evolutionarily well-conserved residues within the TWIST1 WR domain and
used alanine substitution to determine their role in WR domain-mediated protein binding. Co-immunoprecipitation
was used to assay binding affinity between TWIST1 and the NFκB subunit p65 (RELA). Biological activity of this
complex was assayed using a dual luciferase assay system in which firefly luciferase was driven by the interleukin-8
(IL-8) promoter, which is upregulated by the TWIST1-RELA complex. Finally, in order to inhibit the TWIST1-RELA
interaction, we created a fusion protein comprising GFP and the WR domain. Cell fractionation and proteasome
inhibition experiments were utilized to elucidate the mechanism of action of the GFP-WR fusion.
Results: We found that the central residues of the WR domain (W190, R191, E193) were important for TWIST1
binding to RELA, and for increased activation of the IL-8 promoter. We also found that the C-terminal 245 residues
of RELA are important for TWIST1 binding and IL-8 promoter activation. Finally, we found the GFP-WR fusion
protein antagonized TWIST1-RELA binding and downstream signaling. Co-expression of GFP-WR with TWIST1 and
RELA led to proteasomal degradation of TWIST1, which could be inhibited by MG132 treatment.
Conclusions: These data provide evidence that mutation or inhibition of the WR domain reduces TWIST1 activity,
and may represent a potential therapeutic modality.
Keywords: TWIST1, RELA, WR domain, Protein-protein interactions, Protein degradation
* Correspondence: cglackin@coh.org
1City of Hope, 1500 E Duarte Rd, Duarte, CA 91010, USA
Full list of author information is available at the end of the article
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Roberts et al. BMC Cancer  (2017) 17:184 
DOI 10.1186/s12885-017-3169-9
Background
The majority of cancer deaths are the result of tumor cells
metastasizing beyond their original niche [1]. Dissemi-
nated disease is difficult to resect and may be genetically
different to the primary tumor [2]. Moreover, acquisition
of drug resistance further complicates effective therapeutic
approaches. In ovarian cancer in particular, late stage at
discovery and drug resistance are major challenges [3, 4],
resulting in five year survival rates of approximately 25%
[3, 5]. Thus, in ovarian and other cancers, a novel thera-
peutic strategy capable of addressing both metastasis and
drug resistance is urgently needed.
A promising target for such an approach is the tran-
scription factor TWIST1. TWIST1 expression and activity
is essential in early development but is not retained in
adults. However, many cancers reactivate TWIST1 expres-
sion [6–8]. In both the developmental and cancer con-
texts, TWIST1 drives epithelial to mesenchymal transition
(EMT), in which cells alter their phenotype, including
elongated morphology and expression of cell surface pro-
teins, to facilitate migration and invasion [7]. Enhanced
cellular motility in turn gives rise to mesodermal tissues in
embryogenesis and to metastases in cancer [7, 8]. Fur-
thermore, TWIST1 has been implicated in number of
pro-progression phenotypes in cancers, including angio-
genesis [9], increased cancer cell stemness [10–13], and
cell survival signaling [14, 15] (Fig. 1a).
TWIST1 has well-characterized transcription factor
activity; its dimerization partners and binding site within
target promoters have been elucidated previously [16, 17].
Recently, more studies have focused on the Twist box or
WR domain, comprised of the C-terminal twenty amino
acids of the protein (Fig. 1b). The TWIST1 gene is well
conserved evolutionarily, but this is especially true for the
WR domain; 100% homology is preserved from human to
Xenopus (Fig. 1c). We have previously shown that the WR
domain mediates a binding interaction between TWIST1
and the NF-κB subunit RELA, and that this interaction
leads to transcriptional upregulation of the inflammatory
cytokine interleukin 8 (IL-8) in a manner independent of
TWIST1-DNA binding [18]. Furthermore, Piccinin et al.
demonstrated a binding interaction between the WR
domain and the C-terminus of the tumor suppressor p53,
which led to p53 degradation [19]. Recently, it was
revealed that the WR domain can also bind to the WR
domain of a nearby TWIST1-E47 heterodimer, thereby
creating higher order complexes required for proper tran-
scriptional regulation of target genes [17]. This finding
may explain the finding that altered TWIST1-mediated
transcription of Hoxa9 was responsible for the inability of
prostate cancer cells expressing WR-truncated alleles of
TWIST1 to metastasize in an in vivo model system [20].
Given its importance in mediating not only protein-
protein interactions, but also the DNA binding activity
of TWIST1, we hypothesize that the WR domain is a
potential target to block TWIST1 functions associated
with cancer. To test this hypothesis, we sought specific
residues mediating the interaction with RELA and tested
mutants lacking these residues using our previously
validated model system [18]. We further demonstrate
that a WR domain mimetic can abrogate TWIST1 activ-
ity in vitro, providing further evidence that blocking this
interaction and inhibiting TWIST1 expression could be
an effective cancer therapeutic strategy.
Methods
Cell culture
HEK-293 cells were grown in McCoy’s 5A medium supple-
mented with 10% fetal bovine serum (FBS) and 1% penicil-
lin/streptomycin (P/S). Ovcar4 cells were grown in RPMI
medium with 10% FBS and 1% P/S. All cells were main-
tained at 37 °C and 90% humidity in a tissue culture incu-
bator with 5% CO2 atmosphere. Cells were passaged every
2–4 days as they became confluent, using 0.25% trypsin.
Where indicated, cells were transfected using 5 μL per well
Lipofectamine 2000 (Life Technologies, Carlsbad, CA) in a
total of 2 mL per well of OptiMEM low serum medium
(Life Technologies). Cycloheximide (CHX) was obtained
from Sigma Aldrich (St. Louis, MO) and used at a dose of
20 μg/ml. For CHX studies, cells were transfected using
XtremeGene 9, also from Sigma Aldrich. For proteasome
inhibition studies, MG132 was added to HEK-293 cells in
normal medium four hours after transfection and left on
overnight. A dose of 5 μM was used for fractionated west-
ern studies and 1 μM was used for luciferase assays.
Site directed mutagenesis
The cloning of TWIST1 into the pcDNA4-MycHis vector
has been described previously [18]. The wild type RELA
gene was also cloned into pcDNA4-MycHis, including a
stop codon at the C-terminus to prevent translation of the
Myc-His tag. TWIST1 retained the tag. Amino acid substi-
tution and truncation mutations were introduced using
the QuikChange II site directed mutagenesis kit (Agilent,
Santa Clara, CA) according to the manufacturer’s instruc-
tions and following their recommendations for primer
design. Silent mutations were introduced in tandem with
the desired mutations in order to create or eliminate
restriction sites to facilitate screening for mutants. All mu-
tations were confirmed by Sanger sequencing by the City
of Hope Integrative Genomics Core.
GFP fusion protein
In order to create a competitive inhibitor for TWIST1-
RELA binding, the WR domain from TWIST1 was fused
to eGFP. Briefly, PCR was used to amplify the final 63
nucleotides of the TWIST1 gene (including stop codon)
and add 5’ XhoI and 3’ BamHI restriction sites. The
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PCR fragment and the pEGFP-C3 vector were sub-
jected to XhoI-BamHI double digest (New England
BioLabs, Ipswich, MA) and the two fragments ligated
together. GFP lacking the WR domain was used as a
control, and includes 21 residues at the C-terminus
encoded by the multiple cloning site of the vector. As
a result, the molecular weights of the two GFP pro-
teins are indistinguishable on a western blot. To
achieve equal expression of GFP-WR compared to
unmodified GFP, it was necessary to transfect cells
with three-fold more GFP-WR plasmid versus GFP. A
one to one ratio was sufficient for CoIP illustrated in
Fig. 4C. For all GFP-WR experiments, 4x refers to
GFP-WR only, 3x to a 3:1 ratio of GFP-WR to GFP,
2x to equal amounts of both, 1x to a 1:3 ratio of
GFP-WR to GFP, and 0 to GFP only.
Co-Immunoprecipitation
HEK-293 cells were plated at 500,000 cells per well, in
2 mL normal medium, in a 6 well plate and allowed to
adhere. The next day, medium was replaced with
OptiMEM low serum medium (Life Technologies). Cells
were transfected with various alleles of TWIST1, RELA,
and GFP using Lipofectamine 2000 (Life Technologies).
The following day, cells were detached using trypsin,
washed with PBS, and pelleted. Cell pellets were lysed in
RIPA buffer, and protein concentration was determined
by BCA Protein Assay (Thermo Fisher, Waltham, MA).
50–100 μg total protein (equal between conditions) was
pre-cleared by incubating with 1 μg normal rabbit IgG
(Santa Cruz Biotechnology, Dallas, TX) and 20-30 μL
Protein A/G Agarose beads (Santa Cruz Biotechnology,
sc-2003) on a rocker at 4 °C for 1 h. Water was added to
Fig. 1 TWIST1 is a highly conserved bHLH class transcription factor with multiple functions. a TWIST1 functions in normal development and in small
populations of adult stem cells, where it assists in wound healing. When reactivated in cancers, TWIST1 activates a transcriptional and protein binding
program giving rise to EMT, and thus to metastases. Many studies have also linked re-expression of TWIST1 to the acquisition of drug resistance and
an increase in stemness. Functions in normal tissue are shown in green; in cancer, in red. b Human TWIST1 protein is 202 amino acids in length, with
the N-terminal half of the protein being largely disodered The C-terminal half consists of the basic DNA binding domain (orange), helix-loop-helix
dimerization domain (yellow), and the Twist box or WR domain (blue), which has been shown to be a transactivation domain. c The WR domain is
especially well conserved throughout evolution, with 100% identity between human, mouse, and frog. The central residues appearing in green are
present in all organisms listed, including Drosophila, and for this reason, residues were selected for mutation
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equalize volumes across conditions. Beads were centri-
fuged for 1 min at 3,000 rpm, and equal volumes of super-
natant from each condition were transferred to new tubes,
and incubated with 1 μg rabbit anti-RELA (Santa Cruz
Biotechnology sc-109) or rabbit anti-GFP (Santa Cruz
Biotechnology, sc-8334) antibodies on a rocker at 4 °C.
After 1 h, 20–30 μL (equal between conditions) Protein
A/G Agarose beads were added to each tube, and tubes
were returned to the rocker at 4 °C overnight. The follow-
ing day, unbound protein was removed and beads were
washed five times with 1 mL PBS. Beads were boiled in
20 μL 2x loading dye to release bound protein. Equal
masses of input and equal volumes of immunoprecipitated
protein were used for western blotting.
Cell fractionation
HEK-293 cells were plated and transfected as described
for co-immunoprecipitation above. The following day,
cells were detatched using trypsin, washed with PBS,
and pelleted. Pellets were resuspended in 100 μL hypo-
tonic buffer (10 mM HEPES, 10 mM KCl, 0.1 mM
EDTA, 1 mM Na3VO4, 1.25 mM NaF, 0.4% IGEPAL,
0.5 mM DTT) in the presence of protease inhibitor
(Thermo Fisher, Waltham, MA). Cells were left on ice
15 min to swell, and then lysed by addition of NP-40 to
a final concentration of 0.1%. Nuclei were separated
from cytoplasmic lysate by centrifugation (3000 rpm,
10 min, 4 °C) and washed once in hypotonic buffer with-
out NP-40. Nuclei were then resuspended in 50 μL high
salt buffer (20 mM HEPES, 400 mM NaCl, 1 mM EDTA,
10% glycerol, 1 mM Na3VO4, 1.25 mM NaF, 0.5 mM
DTT) plus protease inhibitor. Vials were shaken for 2 h
at 250 rpm at 4 °C, and then centrifuged (5 min,
14,800 rpm, 4 °C). NaCl concentration was adjusted to
137 mM by addition of water prior to western blotting.
Cycloheximide study
HEK-293 cells were plated at 150,000 or 250,000 per well
in 12 well plates and allowed to adhere overnight. The fol-
lowing day, cells were transfected as described for the
above procedures. On the third day, non-treated cells were
harvested and cycloheximide was added to the remaining
wells. Remaining treated cells were harvested at the indi-
cated time points and used for western blotting.
Western Blotting
Protein was run on 10% resolving polyacrylamide gels
and transferred to PVDF membrane. Membranes were
rinsed with PBS and blocked in 5–10% milk, 1 h at room
temperature or overnight at 4 °C. Membranes were then
incubated with mouse primary antibody in milk with
Tween-20 (Ab Buffer) for 1 h at room temperature or
overnight at 4 °C, and washed in PBS with 0.1% Tween-
20 (PBST). Membranes were then incubated with anti-
mouse secondary antibody in Ab Buffer for 1 h at room
temperature, followed by an additional five PBST
washes. Primary antibodies were: TWIST1, TWIST 2c1a
(Santa Cruz Biotechnology sc-81417) 1:250-1:500; for
RELA, NF-κB p65 F-6 (Santa Cruz Biotechnology sc-
8008) 1:250-1:500; for GFP, GFP B-2 (Santa Cruz Bio-
technology sc-9996) 1:1000; for actin, Sigma Aldrich
A1978 or 2066. Secondary antibodies were HRP conju-
gated anti-mouse and anti-rabbit. Protein was detected
using Blue Devil Film (Genesee) and ECL Plus (Thermo
Fisher) or digital imaging. Quantitation of digital images
was performed using the accompanying software from
Syngene (Frederick, MD) or Carestream MI (Wood-
bridge, CT).
Luciferase assay
Ovcar3 and Ovcar4 cells were plated at 50,000 or 75,000
cells per well, in 500 μL RPMI, in a 24 well plate and
allowed to adhere overnight. Ovcar4 cells were used for
all luciferase assays except for that shown in Additional
file 1: Figure S1. The following day, cells were switched
to OptiMEM medium and transfected using Lipofecta-
mine 2000 at 2 μL per well. Plasmids were: TWIST1 in
pcDNA4, RELA in pcDNA4, Renilla luciferase, and fire-
fly luciferase (FFluc) in pGL3. FFluc was under the con-
trol of the IL-8 promoter; construction of this vector has
been described previously [18]. Empty pGL3 lacking a
promoter was used as a negative control for FFluc ex-
pression. Each condition was tested in triplicate. The
day after transfection, luciferase expression was quanti-
fied using the Dual Luciferase Assay kit (Promega, Madi-
son, WI) according to the manufacturer instructions.
Confocal microscopy
HEK-293 cells were plated at 500,000 per well in glass
bottom 35 mm cell culture dishes, and the next day were
transfected with TWIST1, RELA, and GFP or GFP-WR
as described above. After a further 24 h, cells were
rinsed with PBS and stained for 15 min with DAPI.
DAPI was then replaced with PBS. Images were captured
using a Zeiss LSM700 Confocal Microscope and ZEN
2012 microscopy software (Zeiss AG, Oberkochen,
Germany).
Data analysis and statistics
Western blots were quantified using GeneTools soft-
ware. Data were graphed and analyzed in Microsoft
Excel and GraphPad Prism 6, respectively. Luciferase as-
says were analyzed using one-way ANOVA with correc-
tion for multiple comparisons. For assay testing RELA
mutants, all conditions were compared to all others. For
assays testing TWIST1 mutants and GFP-WR inhibitor,
positive control condition was compared to all others.
Positive control conditions are indicated in each relevant
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figure. Cell counts were averages of four counts, and prior
testing has demonstrated that the count is accurate to
within 13%. All error bars represent standard deviation. *,
p < .05; **, p < .01; ***, p < .001; ****, p < .0001 throughout.
Results
Single amino acid changes in the WR domain disrupt
TWIST1-RELA binding
Site-directed mutagenesis was used to generate mutations
in the WR domain of TWIST1. On the basis of their high
evolutionary conservation (Fig. 1c), we selected W190,
R191, and E193 for mutation to alanine (W190A, R191A,
E193A alleles, respectively). The ΔWR allele, in which all
twenty amino acids of the WR domain have been deleted,
was created previously as described elsewhere [18]. Mu-
tants were screened by restriction digestion and confirmed
by sequencing (data not shown). All alleles are shown
schematically in Fig. 2a. In order to determine the contri-
bution of individual amino acids in the WR domain to
TWIST1-RELA binding, we transiently expressed RELA
and all TWIST1 alleles in HEK293 cells and performed
co-immunoprecipitation (CoIP). Following RELA pull-
down, western blotting showed that as demonstrated pre-
viously, truncation of the entire WR domain reduced
TWIST1 co-precipitation to basal levels. W190A, R191A,
and E193A mutations reduced TWIST1 co-precipitation
by 50-60%. A triple mutant with W190A, R191A, and
E193A mutations also reduced RELA binding by 60%,
with less variability (Fig. 2b-c).
Ability of mutant TWIST1 to drive expression of IL-8 is
reduced
We have previously established that formation of a
TWIST1-RELA complex upregulates IL-8 expression by
2-2.5 fold over RELA alone, and that prevention of bind-
ing by truncating TWIST1 returns IL-8 expression to
basal levels [18]. In order to determine the effect of
W190A, R191A, and E193A mutations on IL-8 promoter
activity, we performed a dual luciferase assay in which
firefly luciferase (FFluc) was under the control of the IL-
8 promoter. As expected, exogenous expression of RELA
in Ovcar4 cells gave rise to a basal level of IL-8 driven
FFluc, which was increased by co-expression of, and
thus binding with, TWIST1 (Fig. 2d). Mirroring the phe-
notypes seen in our CoIP experiments above, W190A,
R191A, and E193A mutations reduced expression of
FFluc by 50%, and the triple mutant reduced FFluc
expression a further 10–20% compared to the single
point mutants (Fig. 2d). Similar results were obtained
using the cell line Ovcar3 (Additional file 1: Figure S1),
but a better range of IL-8 promoter induction was
achieved in Ovcar4, and this line was selected for all
subsequent functional assays.
RELA C-terminus is required for TWIST1 binding
While we have shown that the TWIST1 C-terminus is
required for complex formation with RELA, the required
residues of RELA remained unknown. In order to locate
this site, we created a truncation mutant of RELA, Δ307
(Fig. 3a). Site directed mutagenesis was employed to
insert a stop codon directly following the coding
sequence for the REL homology domain, a well-
conserved domain that has been structurally charac-
terized [21]. CoIP of RELA revealed that truncation
of RELA reduced co-precipitation of TWIST1 by
approximately 90% (Fig. 3b-c). Truncating both pro-
teins resulted in a greater loss of binding; under these
conditions, only 1.86% of wild type levels of TWIST1
was detectable following CoIP (Fig. 3b).
RELA C-terminus is required for IL-8 activation, independ-
ent of TWIST1 mutation status
In order to verify that loss of binding between RELA Δ307
and TWIST1 impacted IL-8 expression, we again utilized
a dual luciferase assay. As expected, RELA truncation was
able to reduce FFluc expression (Fig. 3d). However, this
phenotype was independent of TWIST1; in the absence of
TWIST1, RELA Δ307 produced only 30% of wild-type
IL-8 promoter activity. TWIST1 expression upregulated
IL-8-driven FFluc approximately two-fold, regardless of
RELA status. As seen previously, co-expression of triple
mutant TWIST1 with RELA led to an intermediate
phenotype, for both WT and Δ307 alleles of RELA
(Fig. 3d). Thus, we conclude that the domains required for
both IL-8 transactivation and complexing with TWIST1
are contained within the relatively uncharacterized
C-terminus of RELA.
Creation of a GFP-WR domain fusion protein
Given the demonstrated role for the WR domain in
RELA binding, as well as in the transcription factor ac-
tivity of TWIST1 [17, 20], we propose that this domain
is an attractive target for therapeutic intervention. To
test whether the WR domain could act as a competitive
inhibitor of TWIST1-RELA binding, the WR domain
was fused to GFP in the pEGFP-C3 vector (Fig. 4a).
Empty pEGFP-C3 encodes GFP followed by 21 residues
encoded by the multiple cloning site. We therefore used
this vector as a negative control, since its protein prod-
uct would be of the same size as GFP-WR (Fig. 4a). Both
forms of GFP could be expressed to similar degrees in
HEK293 cells (Fig. 4b).
GFP-WR fusion protein reduces TWIST1-RELA binding and
IL-8 activation
To determine the effect of GFP-WR on TWIST1-RELA
binding, we performed CoIP analyses. Total GFP expres-
sion in transfected cells was held constant across all
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conditions by supplementing GFP-WR with control
GFP. RELA pulldown revealed that levels of TWIST1
co-precipitated were reduced in a dose dependent fash-
ion with increasing GFP-WR expression (Fig. 4c). GFP
pulldown revealed that TWIST1 was co-precipitated in a
dose-dependent manner with increasing GFP-WR ex-
pression (Fig. 4d). These findings suggest that GFP-WR
is interacting with TWIST1 via WR-WR binding, an
interaction illustrated by recent studies of higher order
TWIST1 complexes [17]. In order to determine whether
GFP-WR-mediated inhibition of TWIST1-RELA binding
impacted downstream signaling, we again employed a
dual luciferase assay to quantify IL-8 promoter activity.
As expected, GFP-WR expression led to a dose-
Fig. 2 Mutation of the WR domain abrogates TWIST1 interaction with RELA. a Schematic representation of TWIST1 alleles used. Triple mutant
contains W190A, R191A, and E193A mutations. b Co-IP reveals that single amino acid substitutions in the WR domain affect TWIST1-RELA binding, with the
triple mutant producing a greater reduction in binding. c Quantitation of duplicate CoIP western blots. TWIST1 mutations lead to 50–60% reduction in
RELA binding on average. Graphed is the ratio of TWIST1 to RELA, each normalized to its input for each condition. d Dual luciferase assay demonstrates
that IL-8 promoter driven luciferase activity, a surrogate for IL-8 activation by the TWIST1-RELA complex, is influenced by TWIST1 mutation. As seen in the
CoIP, single amino acid substitutions reduce FFluc expression by about 50% with respect to RELA alone, with the triple mutant producing a
greater reduction. Graph represents firefly luciferase expression normalized to renilla luciferase for each condition. Error bars represent
standard deviations of biological triplicate experiments. WT TWIST1 condition was used as the basis for statistical comparisons. pGL3 lacking
the IL-8 promoter was used as a negative control. ***, p < .001; ****, p < .0001
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dependent reduction in FFluc expression (Fig. 4e). Thus,
the TWIST1-driven IL-8 pathway can be inhibited by
direct competition using the WR domain.
GFP-WR fusion protein leads to TWIST1 degradation
As GFP-WR was primarily expressed in the cytoplasm
of transfected cells (Additional file 1: Figure S2), we
hypothesized that GFP-WR was sequestering TWIST1
in the cytoplasm. In order to test this hypothesis, we iso-
lated cytoplasmic and nuclear cell fractions and analyzed
the levels of TWIST1 found in each. Western blot of
fractionated cells showed that in both cytoplasmic and
nuclear fractions, the protein levels of TWIST1 and GFP
decreased as the proportion of GFP-WR transfected was
Fig. 3 Truncation of RELA reveals TWIST1 binding domain is also required for IL-8 regulatory activity. a Schematic representation of RELA alleles. b CoIP
shows that expression of truncation mutants of either TWIST1 or RELA prevents most binding between TWIST1 and RELA. Co-expression of both truncation
mutants further reduces binding, validating the truncated domains as required binding sites for their counterpart proteins. RELA Δ307 bands have been
shown separate from WT due to difference in electrophoretic mobility on account of reduced size. c Quantitation of duplicate western blots
following CoIP of TWIST1 with indicated RELA alleles. Δ307 mutation reduced protein binding by 90% on average. Graphed is the ratio of
TWIST1 to RELA, each normalized to their respective inputs. d Dual luciferase assay reveals that while the Δ307 allele of RELA reduces
TWIST1-mediated upregulation of IL-8 when compared to WT RELA, the same trend is seen in the absence of TWIST1. This suggests that the
C-terminal portion of RELA is required not only for TWIST1 binding, but also for proper transcriptional activity. Graph represents firefly luciferase expression
normalized to renilla luciferase for each condition. Error bars represent standard deviations of biological triplicate experiments. WT TWIST1 +WT RELA
condition was used as the basis for statistical comparisons. pGL3 lacking the IL-8 promoter was used as a negative control. ***, p< .001; ****, p< .0001
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Fig. 4 Competitive inhibition of TWIST1 WR domain binding. a Schematic representation of GFP alleles used. GFP contains 23 amino acids encoded
by the multiple cloning site of the vector at its C-terminus. GFP-WR contains the first two such amino acids (Leu-Glu encoded by XhoI restriction site),
followed by the 20 amino acids of the WR domain. Thus, the two alleles have indistinguishable molecular weights. b Left, fluorescent microscopy
shows that GFP and GFP-WR are expressed at similar levels and in similar patterns in HEK-293 cells. Scale bar, 100 μm. Right, Western blot confirms
equal GFP and GFP-WR expression. c CoIP with RELA pulldown reveals that in the presence of increasing GFP-WR expression, TWIST1-RELA binding is
reduced in a dose-dependent manner. d CoIP with GFP pulldown reveals that increasing GFP-WR dose results in more TWIST1 co-precipitated with
GFP. Graph represents ratio of TWIST1 to GFP, normalized to their respective inputs. Error bars, standard deviation of duplicate experiments. e Dual
luciferase assay demonstrates that as seen in the RELA CoIP, there is a dose dependent drop in IL-8 driven luciferase expression with increasing dose
of GFP-WR inhibitor. Graph represents firefly luciferase expression normalized to renilla luciferase for each condition. Error bars represent standard
deviation of biological triplicate experiments. GFP without GFP-WR condition was used as the basis for statistical comparisons. pGL3 lacking the IL-8
promoter was used as a negative control. ****, p < .0001
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increased (Fig. 5a). This suggested that rather than se-
questration, the interactions between these proteins may
lead to their degradation, as seen previously following al-
tered binding of TWIST1 to partner proteins [19, 22]. In
order to test this hypothesis, we transfected HEK-293
cells with TWIST1, RELA, and either GFP or GFP-WR
and after 24 h, treated with cycloheximide (CHX) to pre-
vent further protein production. TWIST1 was degraded
more quickly in cells expressing GFP-WR than in those
expressing GFP (Fig. 5b), suggesting that GFP-WR leads
to TWIST1 turnover. To determine if this process was
dependent on proteasomal activity, we transefcted HEK-
293 cells and treated them with the proteasome inhibitor
MG132 overnight. Western blots show that MG132 was
able to increase the levels of TWIST1 and GFP by up to
two fold in the cytoplasmic fraction of these cells
(Fig. 5c). Finally, in order to determine the effect of pro-
teasome inhibition on IL-8 promoter activity, a dual
luciferase assay was once again employed. Treatment
with MG132 following GFP-WR expression increased
IL-8 promoter activity two fold, correlating with
increased TWIST1 expression observed following
MG132 treatment (Fig. 5d).
Discussion
We and others have shown that the TWIST1 WR do-
main is important for TWIST1 protein binding and
transcription factor activities, and here we have analyzed
further the specific interaction between TWIST1 and
RELA. We demonstrated previously that the WR do-
main was required for the formation of a complex be-
tween these two proteins, but that TWIST1-DNA
binding was dispensable [18]. We further showed that
the production of IL-8 was reduced by loss of binding as
a result of deleting the WR domain [18]. In the present
study, we identified three highly conserved residues
within the WR domain and mutated each to alanine in
order to ascertain their role in TWIST1 activity. We ob-
served that all three mutations led to a 50% reduction in
TWIST1-RELA co-precipitation and downstream IL-8
promoter activity; the triple mutant further reduced
RELA binding and IL-8 promoter activity. These find-
ings suggest that the central region of the WR domain
(W190, R191, E193) is important for protein-protein in-
teractions involving TWIST1. This function may explain
their evolutionary sequence conservation.
It is important to note that the data presented here
cannot preclude the existence of additional or intermedi-
ary protein members of the TWIST1-RELA complex,
although their overexpression in HEK-293 cells in the
absence of other exogenous cofactors and previous work
on these two proteins suggests that a direct binding
interaction is likely [23].
Further studies, including structural biology approaches,
will be necessary to fully elucidate the TWIST1-RELA
binding interaction. No crystal structure for full length
TWIST1 presently exists. However, a computational
model predicts a helical structure for much of the WR do-
main and also suggests an interface that binds to p53 [19].
The R191 residue in particular was responsible for dis-
rupting p53 post-translational modifications, leading to
p53 degradation [19]. We have shown here that the WR
domain interacts with a RELA transactivation domain
downstream of the REL homology domain, which also has
yet to be structurally characterized. Other groups have
shown also that the WR-domain of TWIST1 binds to
Sox10 and Runx3 [24, 25], and additional binding partners
may yet be identified. Further studies are needed to
recognize structural motifs that may predict TWIST1-
binding sites on additional cellular proteins.
Having shown that the bHLH domain of TWIST1 was
not required for IL-8 regulation [18], we hypothesized
that separation of function would be possible, and that
we could independently study the DNA binding and
protein binding functions of TWIST1. However, Gajula
et al. showed that TWIST1 lacking the WR domain was
unable to promote metastasis in an in vivo model of
prostate cancer. Specifically, they found that TWIST1-
mediated regulation of Hoxa9 at the transcriptional level
was responsible for the phenotype they observed [20]. A
possible explanation for this finding is that TWIST1-
responsive promoters can contain tandem E-box
sequences. Both E-boxes are bound by TWIST1 hetero-
dimers, which then interact via their WR domains to
form a transient tetramer [17]. Thus, whether directly
bound to DNA or bound to protein cofactors, there is
now strong evidence that WR domain interactions lie at
the heart of many TWIST1 signaling processes.
Targeting of the WR domain offers a potential thera-
peutic approach to simultaneously disrupt protein bind-
ing, transcription factor activities, and rate of recycling
of the TWIST1 protein. To test this hypothesis, a GFP
fusion protein including the WR domain was created
and used to inhibit normal TWIST1-RELA complex for-
mation and IL-8 promoter regulation. The GFP-WR fu-
sion protein successfully reduced TWIST1 activity, and
led to TWIST1 degradation in a dose dependent man-
ner. The finding that TWIST1 was co-precipitated with
GFP-WR suggests that these proteins are interacting via
their WR domains, blocking WR domain binding to
other partner proteins.
Importantly, TWIST1 inhibition via blocking of bind-
ing and subsequent degradation has a natural analogue,
supporting its efficacy: TWIST1 is known to be seques-
tered by HLH inhibitor of DNA binding (Id) family
members 2 and 4, preventing its binding to other part-
ners [26, 27]. Moreover, mutations in TWIST1 found in
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Fig. 5 Mechanism of GFP-WR action. a Fractionation experiments reveal an overall decrease in TWIST1 and GFP protein expression in the cytoplasm as
the level of GFP-WR co-expressed in cells increases. TWIST levels also decrease in the nucleus, but GFP-WR is not expressed in the nuclear fraction.
This suggests that GFP-WR expression may lead to TWIST1 degradation. Histone H1 and alpha tubulin were used as nuclear and cytoplasmic
markers, respectively. b Cycloheximide (CHX) treatment of cells co-transfected with TWIST1 and either GFP or GFP-WR. Left, representative
western blot demonstrates more rapid turnover of TWIST1 in the presence of GFP-WR than GFP. Right, quantitation of duplicate experiments.
c TWIST1 and GFP levels in the cytoplasmic fraction show a 2-fold increase upon MG132 treatment at 1x dose of GFP-WR (biological duplicate
experiments, each condition normalized to its 0 GFP-WR control). d Dual luciferase assay demonstrates that MG132 treatment increases IL-8
driven FFluc expression. Graph represents firefly luciferase expression normalized to renilla luciferase for each condition. Error bars represent
standard deviations of biological triplicate experiments. GFP without GFP-WR or MG132 was used as the basis for statistical comparisons. pGL3
lacking the IL-8 promoter was used as a negative control. Error bars, standard deviation. *, p < .05
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Saethre-Chotzen Syndrome that prevent its dimerization
and nuclear translocation have been shown to lead to
degradation of the protein [22].
Future work will focus on further characterization of
TWIST1 turnover and GFP-WR mechanism. It is pos-
sible that binding between the WR domains of TWIST1
and GFP-WR alone is sufficient to lead to TWIST1 deg-
radation, but it is also possible that the GFP component
of the fusion protein contributes to TWIST1 inhibition.
For instance, the size of the protein may block other
TWIST1 binding partners from binding, or prevent
post-translational modifications of TWIST1 required for
its stability or activity. To assess the efficacy of the WR
domain alone, we have created a WR domain peptide
fused to a nona-arginine cell penetrating leader
sequence, and will test its ability to inhibit TWIST1
binding and activity. Use of this peptide design is sup-
ported by the efficacy of a similar peptide mimic of
BRCA1-IRIS, which led to degradation of IRIS and
reversal of its pro-drug resistance effects [28].
Future work will also focus on additional therapeutics
against TWIST1. We have already demonstrated the effi-
cacy of siRNA against TWIST1 delivered using multiple
nanoparticle platforms. Dendrimers carrying siRNA
against TWIST1 reduced migration in vitro and homed
to tumors in a xenograft model of triple negative breast
cancer in mice [29]. In addition, mesoporous silica parti-
cles carrying chemically modified siRNA reduced tumor
size in an in vivo melanoma model via reduction of
angiogenesis [30] and reversed cisplatin resistance in an
ovarian cancer model, leading to reduction of tumor
growth in mice [31]. We have also shown that cells ex-
hibited reduced Akt signaling and in vivo survival in re-
sponse to cisplatin treatment when TWIST1 expression
was reduced by shRNA [15].
TWIST1 is an attractive target for novel therapies: it is
rarely expressed in adult tissues, reducing the chance of
off-site effects [32], and it plays a role in multiple cancer
processes correlated with poor outcome, such as meta-
static spread, angiogenesis, resistance to apoptosis, drug
resistance pathways, and cancer cell stemness (Fig. 1a)
[7, 9, 11, 14, 33, 34]. Further development of multiple
approaches to TWIST1 targeting is warranted, as pa-
tients at the highest risk, and who therefore tend to have
the fewest therapeutic options, may be in a position to
benefit most from TWIST1-targeted treatment.
Conclusions
We have shown here that the formation of a TWIST1-
RELA complex is partially dependent on the well con-
served W190, R191, and E193 residues of the TWIST1
WR domain, and that mutations at these positions re-
duce binding and downstream IL-8 promoter activation.
These effects may be the result of lower binding affinity
due to changes to the binding interface or to destabilization
of the WR domain fold. We have further showed that the
C-terminus of RELA is involved both in TWIST1 binding
and IL-8 promoter activation. Finally, we have demon-
strated a competitive inhibitor of the TWIST1 WR domain
has therapeutic potential, leading to the degradation of
TWIST1 protein. Further investigations of WR-mediated
binding interactions and development of TWIST1-targeted
therapies may be of great value to patients suffering from
advanced, drug resistant carcinomas.
Additional file
Additional file 1: Figure S1. TWIST1 mutation decreases IL-8 promoter
activity in Ovcar3 cells. Replicating the experiment shown for Ovcar4 in
Fig. 2 shows a similar trend in the Ovcar3 cell line. As Ovcar3 showed a
smaller degree of induction with TWIST1 expression, Ovcar4 was used as
the cell line of choice for remaining functional assays. Figure S2. Confocal
images of GFP allele localization. GFP lacking the WR domain is visible
throughout the cell, including the nucleus, as indicated by DAPI staining.
GFP-WR signal appears distinct from DAPI-positive nuclei. (PDF 456 kb)
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